^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yervoy (ipilimumab)

    i
    Other names: BMS-734016, MDX 101, MDX 010, MDX-CTLA-4, MDX-CTLA5, BMS734016, MDX-010, MDX010, BMS 734016
    Company:
    BMS, Ono Pharmaceutical
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    1d
    ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab (clinicaltrials.gov)
    P4, N=90, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    BRAF (B-raf proto-oncogene) • IFNA1 (Interferon Alpha 1)
    |
    Signatera™
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1d
    A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=50, Terminated, Incyte Corporation | N=136 --> 50
    Enrollment change
    |
    Yervoy (ipilimumab) • epacadostat (INCB024360)
    1d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    1d
    HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    2d
    C6461013: Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Pfizer | N=78 --> 138
    Enrollment change • Trial initiation date
    |
    Yervoy (ipilimumab)
    4d
    Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality. (PubMed, Clin Cancer Res)
    These findingssuggest that LDRT combined with ICB is safe and may contribute to immunomodulatory activity in immune-excluded tumors. CD8⁺ TIL dynamics, DNA repair responsiveness, and TME composition may predict response and merit further validation in controlled larger studies.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • aspirin • celecoxib oral
    5d
    Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report. (PubMed, Front Oncol)
    Two cycles of nivolumab plus ipilimumab were performed before discovering severe cervical spine pain. Here we show (1) robust CD3+ and CD20+ infiltration in primary tumors and metastases, with immune cells in direct contact with tumor cells or organized in lymphoid aggregates/tertiary lymphoid structures; (2) PD-L1 overexpression in sRCC and nodal metastasis but absent in post-immunotherapy bone lesions; (3) increased CD163+ macrophages in sRCC and metastases versus ccRCC. This case illustrates that ICIs can induce near-complete eradication of bone metastases; that bone is not an immune-exempt organ, with massive intratumoral immune cell infiltration; and that immediate immune-mediated tumor clearance prevents structural skeletal damage, which merits careful surveillance.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD163 (CD163 Molecule) • CA9 (Carbonic anhydrase 9) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    PD-L1 overexpression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    5d
    Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov)
    P2, N=47, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide
    6d
    A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MTAP (Methylthioadenosine Phosphorylase)
    |
    HER-2 overexpression • MTAP deletion
    |
    MSK-IMPACT • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody • PD-L1 IHC 73-10 pharmDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • navlimetostat (BMS-986504)
    7d
    A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma. (PubMed, Front Immunol)
    However, the metastatic RCC progressed after another 3 months, and the patient received two lines of tyrosine kinase inhibitors (sunitinib and cabozantinib)...Severe cerebral vasculitis requires hospitalization with prompt diagnostic workup and immunosuppressive treatment. Despite the preterm permanent discontinuation of immunotherapy, the patients can benefit from the systemic treatment.
    Journal
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • Cabometyx (cabozantinib tablet)
    7d
    Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    7d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=96, Recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)